The USA India Chambers of Commerce (USAIC) highlighted the annual Union Budget’s significant impact on biopharma and healthcare innovation. The budget showcased new investments, the expansion of clinical trial infrastructure, and strides towards global regulatory alignment. USAIC president Karun Rishi noted the government’s emphasis on biopharma, exemplified by initiatives like Biopharma Shakti and the proposal to establish 1,000 clinical trial sites nationwide.
Rishi praised the allocation of Rs 10,000 crore to Biopharma Shakti over five years, underscoring its role in advancing a technology-driven biopharma ecosystem. He also lauded the plan for a network of 1,000 clinical trial sites as a crucial move to bolster India’s clinical research infrastructure. According to Rishi, these steps align with USAIC’s longstanding advocacy for capacity building and ethical, high-quality clinical trials to position India as a global biopharma innovation leader.
The USAIC president welcomed the government’s commitment to enhancing the Central Drugs Standard Control Organization to meet global standards. He stressed the importance of credible regulation, evidence-based decision-making, and predictable approval timelines for India’s pharmaceutical competitiveness. Rishi highlighted the significance of these priorities discussed during USAIC’s BioPharma Strategy Session in Delhi, emphasizing the need for industry-government collaboration.
Rishi commended Budget 2026 for its forward-looking approach, focusing on growth, inclusion, and fiscal responsibility amid global uncertainties. He noted the government’s emphasis on skills, employability, research, and innovation as key drivers of India’s future-ready growth trajectory. USAIC praised the Finance Minister and the Government of India for their strategic measures across critical sectors, anticipating a positive impact on India’s global biopharma innovation standing.
